Field effectiveness of combination antiretroviral prophylaxis for the prevention of mother-to-child HIV transmission in rural Zambia by Gartland, Matthew G. et al.
Field effectiveness of combination antiretroviral prophylaxis for
the prevention of mother-to-child HIV transmission in rural
Zambia
Matthew G GARTLAND, BA1,2, Namwinga T CHINTU, MD2, Michelle S LI, MS2, Mwila K
LEMBALEMBA, MD3, Saziso N MULENGA, MSc2, Maximillian BWEUPE, MD3, Patrick
MUSONDA, PhD2,4, Elizabeth M STRINGER, MD, MSc2,5, Jeffrey SA STRINGER, MD2,5, and
Benjamin H CHI, MD, MSc2,5
1Vanderbilt University School of Medicine; Nashville, TN, USA
2Centre for Infectious Disease Research in Zambia; Lusaka, Zambia
3Zambian Ministry of Health; Lusaka, Zambia
4University of East Anglia; Norwich, UK
5University of North Carolina at Chapel Hill; Chapel Hill, NC, USA
Abstract
Objective—To evaluate the effectiveness of maternal combination antiretroviral prophylaxis for
prevention of mother-to-child transmission of HIV (PMTCT) in a program setting
Design—Prospective cohort study
Setting—Nine primary care clinics in rural Zambia
Participants—284 HIV-infected pregnant women at ≥28 weeks gestation initiating PMTCT
services between April 2009 and January 2011 and their newborn infants
Intervention—In four “intervention” sites, PMTCT comprised universal combination
antiretroviral prophylaxis (i.e., irrespective of CD4 count) from pregnancy until the cessation of
breastfeeding. In five “control” sites, women received antenatal zidovudine and peripartum
nevirapine, the standard of care at the time. Prophylaxis during breastfeeding was not available in
control sites.
Main outcome measure—Cumulative infant HIV infection and death at 12 months postpartum
Results—At 12 month postpartum, 1 of 104 (1.0%) infants born to mothers at the intervention
sites were HIV-infected, compared to 14 of 116 (12.1%) receiving care in the control sites
(relative risk [RR]: 12.6, 95%CI: 2.2-73.1; P=0.005). When we considered the composite outcome
of HIV infection or death, similar trends were observed in the overall study population (RR: 3.4,
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95%CI: 1.6-7.6; P=0.002) and in a sub-analysis of women with CD4 >350 cells/μL (RR: 3.2;
95%CI: 1.1-9.6; P=0.04).
Conclusions—When compared to PMTCT services based on antenatal zidovudine and
peripartum nevirapine, the provision of maternal combination prophylaxis imparted measurable
health benefits to HIV-exposed infants. Implementation research is needed to further tailor and
optimize these strategies for similar field settings.
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INTRODUCTION
Antiretroviral therapy (ART) during pregnancy improves maternal survival and reduces
infant HIV infection [1]. For those who do not yet require long-term treatment, combination
antiretroviral prophylaxis (ART prophylaxis) can also effectively reduce mother-to-child
HIV transmission in the antenatal, intrapartum, and postpartum periods [2-9]. In the 2010
World Health Organization (WHO) guidelines, maternal ART prophylaxis was included as
one of two recommended options for the prevention of mother-to-child HIV transmission
(PMTCT), as the so-called “Option B” approach [10]. By 2012, however, the WHO clearly
favored maternal three-drug antiretroviral combinations for a number of reasons:
simplification of regimens, integration with comprehensive HIV services, reductions in
maternal morbidity and mortality, and potential for preventing horizontal HIV transmission
to serodiscordant partners [11].
The WHO’s Option B strategy for PMTCT calls for initiation of maternal combination
antiretroviral regimens early in pregnancy (as early as 14 weeks), with continuation until
breastfeeding stops. All infants receive six weeks of either zidovudine (ZDV) or nevirapine
(NVP). Women who require ART for maternal health continue lifelong treatment following
breastfeeding cessation. Despite its introduction in 2010, there are few published reports
about the field implementation of Option B. In a “real world” context, several factors could
affect its public health impact. For example, the successful uptake of the intervention is
critical; yet, studies of the “PMTCT cascade” demonstrate attrition at numerous time points,
even for relatively simple regimens such as single-dose nevirapine [12]. For those who
successfully initiate prophylaxis or treatment, questions around program retention and long-
term drug adherence persist [13-16]. Studies focusing on the field effectiveness of Option B
are urgently needed, particularly as this strategy is scaled up across sub-Saharan Africa. Our
objective was to evaluate the effectiveness of combination ART prophylaxis for PMTCT in
a public health setting in rural Zambia.
METHODS
Setting
The Kafue District is a rural area approximately 40 kilometers south of the Zambia’s capital
city of Lusaka. The district covers 9,400 square-kilometers and, in 2010, had a population of
242,754 [17]. Over the past three years, the antenatal HIV prevalence in the Kafue District
reported by the Ministry of Health was approximately 17% (personal communication, M
Mzumara). The public health sector in the district comprises a network of 14 primary care
clinics – all with outpatient antenatal services – with more complicated patients referred to a
single district hospital.
From 2007 to 2010, PMTCT in the Kafue District followed the Zambian Ministry of Health
guidelines [18]. Opt-out HIV counseling and testing was provided within antenatal clinics
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and diagnosis was established using a rapid antibody test algorithm. HIV-infected women
were referred to 1 of 4 HIV care and treatment units in the district where they underwent
clinical and immunologic screening for ART eligibility. Women who met eligibility criteria
for HIV treatment — CD4 cell count ≤350 cells/μL or WHO clinical stage 3 or 4 — were
prescribed ART. Those who did not meet these criteria were prescribed twice-daily ZDV
from 28 weeks of gestation onward. At the time of labor, these women were instructed to
ingest a single dose of NVP, typically dispensed at an earlier visit, followed by a 1-week
zidovudine-lamivudine (ZDV-3TC) “tail.” HIV-exposed newborns received a single-dose of
NVP within the first 72 hours, followed by seven days of ZDV prophylaxis. Mothers were
encouraged to exclusively breastfeed for 6 months and then provide complementary feeds
with continued breastfeeding until 24 months if they remained HIV negative. In accordance
with national guidelines, additional maternal or infant antiretroviral prophylaxis was not
provided during breastfeeding. For our primary comparisons (see below), we describe this
PMTCT protocol as the “standard of care” and individuals receiving this care as the “control
group.”
Pilot PMTCT program in Kafue District
In April 2009, the Zambia Ministry of Health implemented a four-facility demonstration
project in Kafue District offering ART prophylaxis to all HIV-infected pregnant women
irrespective of clinical stage or CD4 cell count. Our group at the Centre for Infectious
Disease Research in Zambia (CIDRZ) provided technical assistance and support in its
design and oversight. We developed an integrated clinic model where pregnant women
diagnosed with HIV were provided CD4 screening and WHO clinical staging within the
antenatal clinic setting. Those who met criteria for HIV treatment were immediately started
on ART and advised to continue it for life. Women who did not meet criteria for HIV
treatment were offered ART prophylaxis starting at 28 weeks of gestation, with a plan to
stop the regimen at the cessation of breastfeeding. A nucleoside reverse transcriptase
inhibitor backbone of ZDV and 3TC was preferentially prescribed. NVP was prescribed as
the “third drug” when the woman’s CD4 was ≤250 cells/μL; when the CD4 count was above
this threshold, we dispensed efavirenz (EFV) or lopinavir-ritonavir (LPV/r) [19,20]. In cases
of anemia, ZDV was substituted with tenofovir (TDF), abacavir (ABC), or stavudine (D4T)
[21]. Infant feeding counseling corresponded with the standard of care: exclusive breast-
feeding until 6 months with the addition of complementary feeding until 24 months. For our
primary comparisons, we describe the patients receiving these services as the “intervention
group.”
Study activities
The pilot program presented a unique opportunity to evaluate the field effectiveness of
combination ART prophylaxis for PMTCT in a public health setting. Using a quasi-
experimental design, we enrolled a cohort of pregnant women seeking care across the 4 pilot
sites into the intervention group. To provide a contemporaneous control group, we also
enrolled pregnant women from 5 other government clinics providing PMTCT according to
the prior standard of care. (The fifth control site was added due to slow enrollments at one
rural health facilities.) Across all 9 sites, HIV-infected pregnant women who had been
screened for ART eligibility were approached from 28 weeks gestation onward to
participate. Gestational age was estimated based on reported last menstrual period.
Ultrasound confirmation was not available due to the limited resources in these rural areas.
The study was described and written informed consent obtained. Specific reasons for non-
participation were not collected as part of routine clinical practice or by study staff;
therefore, we were unable to include them in our final analyses.
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All participants in both groups of this prospective cohort study received intensive clinical
and laboratory monitoring. Following enrollment, they were scheduled for 2 week, 4 week,
and 8 week visits. Clinical assessments were conducted immediately after delivery and at 6
weeks, 3 months, 6 months, and 12 months postpartum. We tested infants for HIV infection
at birth, 6 weeks, 6 months, and 12 months of life with the Roche Amplicor version 1.5
DNA PCR assay with manual extraction (Roche Diagnostics, Branchburg, NJ, USA). We
required a second positive specimen from a separate blood draw to confirm infant infection.
We evaluated medication adherence in the intervention group using the medication
possession ratio, a measure of the cumulative number of days late for pharmacy refills
divided by total days on therapy [22]. Participants with missed visits were followed-up at
home by community health workers and reminded about study visits. We sought to enroll
320 HIV-infected pregnant women: 160 from intervention sites and 160 from control sites.
Because of recognized differences in patient volume at participating facilities, enrollment at
any single site was capped at 40 participants. This sample size was based on an expected
decrease in HIV transmission from 18% to 4% [23,24], assuming 80% power and a 0.05
two-sided significance level. We used the formula published by Hayes and Bennett [25]
with an estimated coefficient of variation of 0.6.
Statistical analysis
Our primary outcomes were (1) infant HIV infection and (2) infant HIV infection or death,
measured at 6 weeks, 6 months, and 12 months postpartum [26]. The primary study
population included all live born infants. Infants categorized as lost to follow-up were
censored at the time of last visit and thus did not contribute to later point estimates for HIV
infection or death.
We compared baseline demographic and clinical characteristics between groups using
Fisher’s exact test for categorical variables and non-parametric Wilcoxon rank sum tests for
continuous variables. To measure differences in breastfeeding and follow-up losses,
important potential confounders to our analysis, we conducted Kaplan-Meier analyses and
adjusted Cox proportional regression. Age, CD4 count, WHO clinical stage, renal function,
liver function, parity, time on ART prophylaxis during pregnancy, and gestational age were
included in the multivariate Cox models. For our primary analyses, we used a log-linked
binomial regression model to estimate the relative risk (RR) of our primary outcomes
between the intervention and control groups using generalized estimating equations with an
exchangeable correlation structure to account for clustering at the site level. We calculated
95% confidence intervals using exact binomial methods. Because of differences in our
comparison groups due to early ART referrals in the control sites, we conducted a secondary
analysis restricted to infants whose mothers had a CD4 cell count of >350 cells/μL. We
performed all analyses with SAS version 9.1.3 (SAS Institute, Cary, NC). The study was
approved by the Biomedical Research Ethics Committee at the University of Zambia
(Lusaka, Zambia) and the Institutional Review Boards at the University of North Carolina at
Chapel Hill (Chapel Hill, North Carolina, USA) and the University of Alabama at
Birmingham (Birmingham, Alabama, USA).
RESULTS
We recruited participants from April 2009 to January 2011. In the four intervention sites,
2,469 pregnant women agreed to HIV testing and 451 (18.3%) were diagnosed with HIV.
Among those identified as HIV-infected, 218 (48.3%) initiated ART prophylaxis; of these,
143 (65.6%) enrolled in this study. In the five control sites, 3,158 pregnant women agreed to
HIV testing, of which 513 (16.2%) were diagnosed with HIV. All women were offered
PMTCT according to the standard of care and 369 (71.9%) received at least one
dispensation of antenatal ZDV. Of these 141 (38.2%) enrolled in the study.
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Of the 284 total participants, 4 (1.4%) withdrew from the study and 10 (3.5%) were lost to
follow-up prior to delivery (Figure 1). At delivery, 7 (2.5%; 95% CI 1.0-5.3%) stillbirths
were documented. Our analysis cohort comprised 263 live born infants for the primary
analysis: 129 in the intervention group and 134 in the control group. At 12 months, 104
mother-infant pairs in the intervention group and 116 mother-infant pairs in the control
group remained active in follow-up including those who had achieved a study outcome.
There was 1 (0.7%) maternal death in the control group. A few differences were noted
between study groups at enrollment (Table 1). These were consistent when this analysis was
limited to mother-infant pairs remaining active in follow-up at 12 months. CD4 at baseline
was lower in the intervention group compared to those in the control (339 vs. 440 cells/μl,
P<0.001). The median time on antiretroviral drugs during pregnancy was shorter in the
intervention group (7.6 vs. 9.1 weeks; P<0.01). Among the 143 women starting ART for
treatment or prophylaxis in the intervention group, the initial prescribed regimen was ZDV
+3TC+EFV (n=74, 52.1%), ZDV+3TC+NVP (n=35, 24.7%), ZDV+3TC+LPV/r (n=14,
9.9%), D4T+3TC+EFV (n=9, 6.3%), D4T+3TC+NVP (n=9, 6.3%), and ABC+3TC+NVP
(n=1, 0.7%). Of 104 women who remained active at 12 months in the intervention group,
100 (96.2%) had documented medication pick-up throughout this period. Among these
women, 70 (70.0%) remained on the ART prophylaxis regimen they initiated at enrollment,
20 (20.0%) had undergone a single-drug substitution, and 10 (10.0%) had 2 drugs replaced
with a fixed-dose combination.
All 129 women with live births in the intervention group and 133 of 134 (99.2%) women in
the control group reported ever breastfeeding (P=1.00). Women in the control group had a
higher risk of breastfeeding cessation prior to 12 months compared to women in the
intervention group (AHR: 2.31; 95%CI: 1.50-3.54) (Figure 2A). In Kaplan-Meier analysis,
80.1% of women in the intervention group remained active in the study at 12 months,
compared to 85.5% in the control group (P=0.13) (Figure 2B). Women in the control group
may have been more likely to be retained in care (AHR: 1.56; 95%CI: 0.63–3.87), but this
finding was not statistically significant. Data on adherence was captured for 103 (99.0%) of
the intervention participants still active in the study at 12 months. Of these, 21 (20.4%) were
found to have poor adherence to the ART prophylaxis (MPR <80%); 46 (44.7%)
demonstrated sub-optimal adherence (80-94%); and 36 (34.9%) had optimal adherence
(≥95%).
HIV infection was documented in 15 infants during longitudinal follow-up: 1 in the
intervention group and 14 in the control group. The timing of HIV infection in the control
group was as follows: at birth (n=1), <4 weeks (n=1), 4 weeks to <3 months (n=4), and 3
months to 12 months postpartum (n=8). The single case of infant HIV infection in the
intervention group occurred at 2 weeks postpartum. Of the 15 HIV-positive infants, 13
(86.7%) had the diagnosis confirmed by a second PCR test and were referred for HIV
treatment. One infant (6.7%) was lost to follow-up and one infant (6.7%) died before a
confirmatory test could be performed. Cumulative risk for HIV infection was consistently
higher in the control group when measured at 6 weeks, 6 months, and 12 months (Figure
3A). The risk of HIV infection at 12 months was 1.0% (1/104) in the intervention group and
12.1% (14/116) in the control group (RR: 12.6, 95%CI: 2.2-73.1; P=0.005). Similar trends
were observed when the composite outcome of infant HIV infection or death was considered
(RR: 3.4, 95%CI: 1.6-7.6; P=0.002; Figure 3B).
Of the 263 live-born infants included in our primary analysis, 154 (58.6%) were born to
mothers with CD4 count > 350 cells/μL at time of regimen initiation. Of these, 95 (61.7%)
were in the control group and 59 (38.3%) in the intervention group. In a secondary analysis
restricted to this sub-population, we were unable to detect differences in HIV infection by 12
months (RR: 2.9, 95%CI: 0.7–13.0; p=0.16; Figure 3C). However, we observed greater risk
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of HIV infection or death among individuals in the control group at 12 months (RR: 3.2;
95%CI: 1.1–9.6; P=0.04; Figure 3D).
DISCUSSION
Use of combination ART prophylaxis during pregnancy and breastfeeding was associated
with a lower rate of infant HIV infection and death when compared to short-course antenatal
ZDV and peripartum NVP. Similar trends were observed among infants whose mothers had
CD4 cell counts >350 cells/μL. These measureable improvements in infant outcomes
support the expansion of ART prophylaxis to all women irrespective of CD4 count, as is
recommended in the WHO’s Option B PMTCT policy.
When our study was first designed and implemented in 2009, the standard of care for
PMTCT in Zambia focused on the timely triage of HIV-infected pregnant women for HIV
treatment. The goal was to urgently identify and initiate treatment for women eligible for
ART. In accordance with WHO recommendations at the time, those who did not meet
eligibility criteria were initiated on short-course zidovudine and peripartum NVP from 28
weeks gestation onward. Antiretroviral prophylaxis during breastfeeding – to either mother
or infant – was not offered. In the ensuing years, however, the science of PMTCT evolved
rapidly. Services similar to those provided in our four Kafue pilot sites have been introduced
as policy across much of Africa [11,27]. In this report, we share our early programmatic
experiences and demonstrate the clear benefits to infant health when services are “upgraded”
from the previous standard of care (i.e., PMTCT as provided in our control sites) to the
current standard of care (i.e., services provided at our intervention sites).
Several clinical trials have demonstrated the efficacy of ART prophylaxis during pregnancy
and through breastfeeding [3-9]. Universally, these regimens have been shown to reduce
mother-to-child HIV transmission; however, study design and primary endpoints have
differed from trial to trial. Perhaps most similar to our study is the Kesho Bora study, a
randomized controlled trial conducted in Kenya, Burkina Faso, and South Africa.
Participants in Kesho Bora were randomized to receive either ART prophylaxis from 28 to
34 weeks gestation through breastfeeding or short-course antenatal ZDV and peripartum
NVP. At 12 months postpartum, the risk of HIV infection or death was lower in the
intervention group when compared to the control group (5.4% vs. 9.5%; P=0.029), findings
that approximate those of our study.
A strength of our study was its focus on field effectiveness, which considered program
attrition over time. However, this “real world” perspective also led to analytical challenges
as well. For example, women who met immunologic criteria for HIV treatment in the
control facilities were immediately referred to the nearest antiretroviral therapy clinic –
typically the Kafue District Hospital – prior to 28 weeks gestation. Women in the
intervention facilities were not referred in the same manner; in our integrated service model,
they could access antiretroviral therapy on site. Because we did not include CD4 eligibility
criteria for the study, these differences in patient management led to imbalances between the
comparison populations. We attempted to account for these differences in our secondary
analysis, which restricted the study population to infants whose mothers had CD4 counts
>350 cells/μL. We were reassured to find that results in this sub-analysis were consistent
with those of the larger study cohort.
We observed a greater than two-fold hazard for stopping breastfeeding before 12 months in
the control group, even after adjusting for baseline participant characteristics. Although we
used a core group of study nurses, many factors — including differences in counseling —
could have contributed to this incongruity. Breastfeeding cessation may also have been
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influenced by the perception that ART prophylaxis during breastfeeding imparts additional
protection against mother-to-child HIV transmission. If confirmed, this change in maternal
infant feeding behavior could present an important collateral benefit of ART prophylaxis.
As part of our analysis, we sought to determine the extent of follow-up losses in our
programmatic cohort. We found that at 12 months of age nearly one-fifth of infants had no
study outcome and could not be traced. This high percentage is concerning, but in line with
other reports. Myer and colleagues showed that 19% of women pregnant at initiation of
ART were lost to follow-up after one year [16]. Similarly, Kaplan and colleagues showed
32% of pregnant women who initiated ART were lost to follow-up after three years [14].
Among women in the intervention group whose infants were retained in care, only 35%
demonstrated optimal adherence to their three-drug regimen as measured by medication
possession ratio. This is significantly lower than previous findings in non-pregnant adults on
ART, but consistent with studies of pregnant women [15,22]. Evidence-based strategies are
clearly needed to improve retention and adherence among pregnant and postpartum
populations, particularly as Ministries of Health move to Option B or Option “B+” (i.e.,
initiation of lifelong antiretroviral therapy in pregnancy irrespective of CD4 cell count for
PMTCT) [27]. Since most women in this population will be asymptomatic [10], there may
be less motivation to adhere to long-term treatment once the risk of HIV transmission to the
infant has passed.
We note several limitations to the current analysis. First, we were unable gather routine data
about reasons behind non-participation in our cohort study. This may have led to
unmeasured selection biases between the groups. Second, since neither the participants nor
the facilities providing the intervention were randomized, our study data may contain
systematic biases. There were several differences between our intervention and comparison
groups. Because of the small number of events, particularly in the intervention group, we
were unable to perform multivariable analyses. However, the most important potential
confounder – maternal CD4 cell count – was examined in greater detail in our secondary
analysis through stratification. Third, owing to the swiftly advancing field of PMTCT, the
standard of care provided at our control sites is no longer the recommended WHO standard.
The lack of antiretroviral coverage during the breastfeeding period, where the majority of
infant HIV infections occurred, is most worrisome. Our study was designed to demonstrate
the incremental health gains made possible by the implementation of the WHO’s Option B
for PMTCT in a field setting.
In summary, our findings demonstrate a significant benefit of maternal ART prophylaxis to
HIV-exposed infants. However, patient attrition and poor adherence among those receiving
combination regimens in the postpartum period could diminish regimen effectiveness and
carry long-term consequences for women on treatment. As country programs seek to
implement antiretroviral regimens of longer duration, particularly after delivery, investments
are urgently needed to improve timely access to care and retention.
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Cohort profile for enrolled mother-infant pairs across participating study sites in Kafue
District, Zambia, April 2009 – January 2012. Intervention denotes women who received
ART prophylaxis. Control indicates women who received ZDV monotherapy with
peripartum nevirapine and ZDV-3TC tail.
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Kaplan-Meier estimates of time to (A) breastfeeding cessation and (B) loss to follow-up
among live born infants of mothers in intervention sites (dashed line) and control sites (solid
line) from birth to 12 months.
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Risk of (A) infant HIV infection and (B) infant HIV infection or death among participants in
the intervention group (white) and in the control group (gray), in the primary analysis at 6
weeks, 6 months, and 12 months. Analysis was based on infants active in study at given time
point. Among infants born to women with CD4 count > 350 cells/μL at time of regimen
initiation (C) infant HIV infection and (D) infant HIV infection or death at 6 weeks, 6
months, and 12 months. P-values denoted above bracket at each time point were calculated
based on log-linked binomial regression model adjusted for clustering using generalized
estimating equations. 95% CI were calculated using exact binomial methods.
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